|Bid||142.32 x 2300|
|Ask||150.08 x 2300|
|Day's Range||149.29 - 149.95|
|52 Week Range||119.41 - 152.38|
|PE Ratio (TTM)||73.54|
|Expense Ratio (net)||0.05%|
An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
AbbVie (ABBV) is focused on advancing its already strong position in the hematologic oncology segment in 2018. The overall hematologic malignancy and solid tumor market in the US is currently worth $87 billion and is expected to reach a market value of $169 billion by 2025. According to estimates from American Cancer Society, SEER, Kantar Health, IMS Institute Healthcare Informatics, Global Oncology Trend Report, and Evaluate Pharma, the total number of cancer patients worldwide is expected to reach 19 million by 2025.
Align Technology (ALGN) increased its expenditure toward consumer marketing by 60% in 2017. The increase in Invisalign treatment adoption rates across the teen and adult segments are driven by the company’s consumer marketing and sales initiatives. Peers Dentsply Sirona (XRAY), Zimmer Biomet Holdings (ZBH), and Henry Schein (HSIC) expect to post SG&A (selling, general, and administrative) expenses of 37.0%, 38.0%, and 20.0%, respectively, in their recent fiscal years.
Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.
This year, the growth factor resumed its outperformance of the value factor, benefiting a host of exchange traded funds along the way. Investors can easily access growth stocks via ETFs, whether be by ...
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.